Health Care [ 7/12 ] | Biotechnology [ 35/73 ]
NASDAQ | Common Stock
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases.
The company develops a proprietary gene editing platform based on CRISPR technology.
It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors.
The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013.
Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 25 | 0.00 Increased by +100.00% | -0.40 Increased by +100.00% |
| May 6, 25 | -0.92 Decreased by -21.05% | -0.66 Decreased by -39.39% |
| Feb 26, 25 | -0.55 Decreased by -139.13% | -0.33 Decreased by -67.38% |
| Nov 1, 24 | -0.75 Decreased by -36.36% | -0.75 |
| Aug 7, 24 | -0.82 Decreased by -46.43% | -0.70 Decreased by -17.14% |
| May 8, 24 | -0.76 Decreased by -7.04% | -0.66 Decreased by -15.15% |
| Feb 28, 24 | -0.23 Increased by +73.86% | -0.54 Increased by +57.41% |
| Nov 3, 23 | -0.55 Increased by +32.10% | -0.57 Increased by +3.51% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 4.66 M Increased by +310.40% | -76.09 M Decreased by -22.82% | Decreased by -1.63 K% Increased by +70.07% |
| Dec 31, 24 | 30.60 M Decreased by -49.03% | -45.40 M Decreased by -140.52% | Decreased by -148.33% Decreased by -371.92% |
| Sep 30, 24 | 61.00 K Decreased by -98.86% | -62.14 M Decreased by -38.03% | Decreased by -101.87 K% Decreased by -11.97 K% |
| Jun 30, 24 | 513.00 K Decreased by -82.23% | -67.61 M Decreased by -67.80% | Decreased by -13.18 K% Decreased by -844.33% |
| Mar 31, 24 | 1.14 M Decreased by -88.48% | -61.95 M Decreased by -35.95% | Decreased by -5.46 K% Decreased by -1.08 K% |
| Dec 31, 23 | 60.05 M Increased by +818.74% | -18.87 M Increased by +65.70% | Decreased by -31.43% Increased by +96.27% |
| Sep 30, 23 | 5.34 M Increased by +12.60 K% | -45.02 M Increased by +16.53% | Decreased by -843.68% Increased by +99.34% |
| Jun 30, 23 | 2.89 M Decreased by -54.62% | -40.29 M Increased by +23.51% | Decreased by -1.40 K% Decreased by -68.56% |